Dalbavancin use in an academic medical center and associated cost-savings.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2019.08.007
Abstract: Dalbavancin is a lipoglycopeptide antibiotic active against gram positive organisms with unique weekly dosing. This retrospective study included 37 patients receiving an average of 2.7 weeks of dalbavancin. 9 (24%) patients were readmitted to the… read more here.
Keywords: medical center; dalbavancin use; center associated; use academic ... See more keywords
122. Dalbavancin Use in Patients with Substance Use Disorders
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.432
Abstract: Dalbavancin, a lipoglycopeptide antibiotic, has an extended half-life that allows for weekly dosing and is an alternative to daily intravenous (IV) antibiotics. The dosing interval has the potential to expand treatment options for more severe… read more here.
Keywords: dalbavancin use; use; substance use; patients substance ... See more keywords
1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz360.892
Abstract: Abstract Background Dalbavancin is a lipoglycopeptide antibiotic active against Gram-positive organisms with an extended half-life that allows for weekly dosing. Initially approved for treating skin and soft-tissue infections, use for more complicated infections provides several… read more here.
Keywords: complicated infections; dalbavancin use; dalbavancin; cost ... See more keywords